Latest Certolizumab pegol Stories
WALTHAM, Mass., Feb.
WALTHAM, Mass., Dec. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that compared to last year's analysis of U.S.
WALTHAM, Mass., Nov.
SAN DIEGO, Oct.
SAN DIEGO, Oct.
Actemra/RoActemra Will Emerge as the Preferred Biological Drug for TNF-Refractory Patients, According to a New Report from Decision Resources WALTHAM, Mass., May 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, in the treatment of rheumatoid arthritis, the market share for TNF-alpha inhibitors will decrease to 63 percent through 2018 as a result of the increasing use of alternative agents to...
Cimzia(R) (certolizumab pegol) now offered in an innovative prefilled syringe designed in partnership with OXO GOOD GRIPS(R) ATLANTA, May 15 /PRNewswire/ --- UCB today announced that Cimzia(R) (certolizumab pegol), the only PEGylated anti-TNF (Tumor Necrosis Factor) approved in the U.S.
Nektar Advanced Polymer Conjugate Technology Used in Cimzia(R) Through Exclusive Nektar-UCB Collaboration SAN FRANCISCO, Calif., May 14 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) confirmed today UCB's announcement that the US Food and Drug Administration (FDA) has approved Cimzia(R) (certolizumab pegol), the only PEGylated anti-TNFa (Tumor Necrosis Factor alpha), for the treatment of adult patients with moderately to severely active rheumatoid arthritis.
-- UCB offers Cimzia(R) (certolizumab pegol), a treatment option for adults with moderately to severely active rheumatoid arthritis and moderate to severe Crohn's disease, to U.S.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.